Hypertension and dyslipidemia are two major cardiovascular risk factors in patients with type 2 diabetes. Cardiovascular Complications of Diabetes is a new study from Decision Resources, Inc., that focuses on the treatment of these two cardiovascular complications in patients with type 2 diabetes. This study finds that, because the needs of patients with type 2 diabetes differ from those of patients with uncomplicated hypertension and dyslipidemia, particular market opportunities exist for new agents that are tailored to address this patient population. Agents that reduce hypertension without affecting glucose metabolism as well as lipid-adjusting drugs that aim to control hypertriglyceridemia and increase high-density lipoprotein (HDL) could find success in the type 2 diabetes population.
Hypertension. New directives calling for a more stringent approach to hypertension diagnosis and treatment, in addition to new, lower blood pressure guidelines for diabetics, are expected to lead to increased diagnosis and treatment rates in all major markets. Moreover, increasing awareness that reducing blood pressure in diabetics can significantly decrease the incidence of cardiovascular disease complications will encourage physicians to treat hypertensive diabetics more aggressively. Angiotensin-converting enzyme inhibitors (ACEIs) will continue to dominate the market for use in patients with type 2 diabetes in all countries under study.
Dislipidemia. Emerging anti-dyslipidemia drugs will likely find market niches by addressing a specific mechanism or combination of mechanisms responsible for particular lipid abnormalities. New introductions will include rosuvastatin (AstraZeneca's Crestor) that has shown superior ability both in lowering low-density lipoprotein (LDL) and in raising HDL levels-a feature particularly welcome in type 2 diabetes patients. We expect the statins to maintain their market-leading position over the forecast period, because physicians are more comfortable with them than the emerging dyslipidemia drugs.
Cardiovascular Complications of Diabetes offers invaluable market intelligence for companies competing in this arena. This study is part of Cardium, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or firstname.lastname@example.org (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or email@example.com (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or firstname.lastname@example.org (e-mail).
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553, or